Sugi Predict

Sugi Predict / Compounds / Maleylacetoacetate

Maleylacetoacetate

Maleylacetoacetate

SCHEMBL380205

O=C(O)C=CC(=O)CC(=O)CC(=O)O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.45
▸ TP53 P04637 1/20 0.45
▸ EGLN1 Q9GZT9 1/20 0.45
▸ EGLN3 Q9H6Z9 1/20 0.45
▸ LDHA P00338 1/20 0.38
▸ SRR Q9GZT4 1/20 0.38
▸ HCAR2 Q8TDS4 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.33
▸ GABRR1 P24046 2/20 0.33
▸ GABRR2 P28476 2/20 0.33
▸ BLM P54132 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ GABRR3 A8MPY1 1/20 0.33
▸ APEX1 P27695 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Maleylacetoacetate SCHEMBL187565 1.00 TSHR (0.45) TSHRTP53EGLN1EGLN3LDHA
Maleylacetoacetate SCHEMBL187863 1.00 TSHR (0.45) TSHRTP53EGLN1EGLN3LDHA
SCHEMBL2780998 0.87 TSHR (0.53) TSHRTP53EGLN1EGLN3LDHA
SCHEMBL2780997 0.87 TSHR (0.53) TSHRTP53EGLN1EGLN3LDHA
SCHEMBL1225122 0.87 TSHR (0.53) TSHRTP53EGLN1EGLN3LDHA
SCHEMBL12568561 0.84 TSHR (0.64) TSHRTP53EGLN1EGLN3HCAR2
SCHEMBL6916408 0.78 LDHA (0.36) TSHREGLN1LDHASRRKDM4E
Maleic Acid SCHEMBL1038087 0.78 TSHR (0.64) TSHRTP53EGLN1EGLN3LDHA
Fumaric Acid SCHEMBL28422912 0.78 TSHR (0.64) TSHRTP53EGLN1EGLN3LDHA
Fumaric Acid SCHEMBL1038089 0.78 TSHR (0.64) TSHRTP53EGLN1EGLN3LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486521-B2 Platform for expressing protein of interest in liver TOOLGEN INCORPORATED (KR) 2025-12-02 — — US claimed
CN-116801892-A Adipogenic cell compositions and methods 旗舰创业股份有限公司 2023-09-22 — — CN claimed
US-20230287461-A1 PLATFORM FOR EXPRESSING PROTEIN OF INTEREST IN LIVER TOOLGEN INCORPORATED (KR) 2023-09-14 — — US claimed
CN-113853372-A Thio-heterocyclic exchange chemistry and uses thereof 弗吉尼亚大学专利基金委员会 2021-12-28 — — CN claimed
CN-112805789-A Method for diagnosing hepatic steatosis 生物预测公司 2021-05-14 — — CN claimed
EP-3752616-A1 COMPOSITIONS AND METHODS FOR GENE EDITING BY TARGETING FIBRINOGEN-ALPHA CRISPR Therapeutics AG (CH) 2020-12-23 — — EP claimed
WO-2019161310-A1 COMPOSITIONS AND METHODS FOR GENE EDITING BY TARGETING FIBRINOGEN-ALPHA CASEBIA THERAPEUTICS LIMITED LIABILITY PARTNERSHIP (US) 2019-08-22 — — WO claimed
US-20120114613-A1 DEFINITIVE ENDODERM CELL POPULATIONS MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) 2012-05-10 — — US claimed
EP-2361966-A1 Mesoderm and definitive endoderm cell populations Mount Sinai School of Medicine of New York University (US) 2011-08-31 — — EP claimed
US-20060276420-A1 GENERATING CELLS FOR CELL REPLACEMENT THERAPY MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY 2006-12-07 — — US claimed
EP-1543110-A4 MESODERM AND DEFINITIVE ENDODERM CELL POPULATIONS SINAI SCHOOL MEDICINE (US) 2006-09-06 — — EP claimed
EP-1543110-A2 MESODERM AND DEFINITIVE ENDODERM CELL POPULATIONS Mount Sinai School of Medicine of New York University (US) 2005-06-22 — — EP claimed
WO-2004098490-A2 MESODERM AND DEFINITIVE ENDODERM CELL POPULATIONS MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) 2004-11-18 — — WO claimed
US-20030017481-A1 Methods for classifying samples and ascertaining previously unknown classes WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2003-01-23 — — US claimed
EP-1043676-A2 Methods for classifying samples and ascertaining previously unknown classes WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2000-10-11 — — EP claimed
CN-122094668-A Preparation method and application of lipid nanoparticle — 2026-05-26 — — CN disclosed
US-12636381-B2 In utero CRISPR-mediated therapeutic editing of genes THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2026-05-26 — — US disclosed
US-5766899-A COMPLEX COMPRISING CIRCUMSPOROZOITE REGION II-CONTAINING POLYPEPTIDE, NUCLEIC ACID BINDING AGENT BOARD OF REGENTS , THE UNIVERSITY OF TEXAS SYSTEM (US) 1998-06-16 — — US disclosed
EP-0785803-A1 USE OF A NON-MAMMALIAN DNA VIRUS TO EXPRESS AN EXOGENOUS GENE IN A MAMMALIAN CELL THE GENERAL HOSPITAL CORPORATION (US) 1997-07-30 — — EP disclosed
WO-1996009074-A1 USE OF A NON-MAMMALIAN DNA VIRUS TO EXPRESS AN EXOGENOUS GENE IN A MAMMALIAN CELL THE GENERAL HOSPITAL CORPORATION (US) 1996-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12636381-B2 In utero CRISPR-mediated therapeutic editing of genes YARS1, TPH1, AARS1 TSHR 1501/4885TP53 276/4885EGLN1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.